AXS25 Summit: Error-Proof Logistics, Value-Based Access, and Coordinated Reimbursement Needed for Expanding Cell and Gene Therapy Pipeline.

Experts at Asembia’s AXS25 Summit highlighted the critical requirements for the expanding cell and gene therapy pipeline: error-proof logistics, value-based access strategies, and coordinated reimbursement models. The summit’s discussions centered around the increasing complexities of delivering these advanced therapies to patients. Speakers emphasized that as the number of cell and gene therapies in development grows, the need for precise and reliable logistics becomes paramount. They also discussed the importance of access strategies that reflect the value these therapies bring. Finally, experts pointed out the necessity of developing coordinated reimbursement models to ensure the financial viability and patient accessibility of these treatments.

Newsflash | Powered by GeneOnline AI
Date: April 30, 2025

Related posts:

COVID-19 Infection Linked to Potential Kidney, GI, and Cardiovascular Issues in Children Trump Administration Order Targets Medical School Accreditation Standards Repetitive Tasks Linked to Reduced mPFC Activity, Increased Putamen Engagement in fMRI Study Novartis to Acquire Regulus Therapeutics for $1.7 Billion to Advance Kidney Disease Drug Development

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後